Focused on

Finding a

Cure

The Syncromune Team is dedicated to developing combination multi-target immunotherapies to fight metastatic solid tumors in a new way

Focused on

Finding a

Cure

The Syncromune Team is dedicated to developing combination multi-target immunotherapies to fight metastatic solid tumors in a new way

Pioneers in Combination Multi-Target Immunotherapy

Syncromune is a privately held, clinical-stage biopharmaceutical company dedicated to the development of SYNC-T, a potentially first-in-class platform immunotherapy designed to address major unmet needs and treatment challenges of incurable metastatic solid tumor cancers. SYNC-T is an in situ personalized cancer therapy engineered to synchronize the location of three components critical to T cell activation and an anti-tumor immune response: patient-specific tumor antigens, immune cells, and our multi-target biologic drug. SYNC-T features a novel proprietary device delivery system that is optimized for combination drug/device immunotherapy. First, the system lyses a portion of a target tumor to rupture tumor cells and release patient-specific tumor antigens into the tumor microenvironment (TME) that help to activate the immune system. Next, the delivery system facilitates the infusion of our proprietary multi-target biologic drug directly into the lysed area of the tumor.

This approach of location synchronization is designed to unite the three critical components together in the TME and lymphatics where the immune system optimally functions. The combination therapy targets numerous mechanisms of cancer, promoting in situ immune activation while also battling immune suppression and minimizing systemic drug exposure. The goal is to educate the immune system and activate T cells that can recognize and attack cancer throughout the body and defend with immune memory. Our lead candidate, SYNC-T Therapy SV-102 for metastatic castration-resistant prostate cancer (mCRPC), is being evaluated in the LEGION-100 U.S., multicenter, Phase 2 trial. For more information, please visit www.legion100trial.com.

Our Mission

We aspire to develop a completely in situ immunotherapy platform technology optimized for solid tumor cancers that achieves high response rates with potentially curative efficacy

Our Values

C

Caring

Every member of the Syncromune team is inspired by the opportunities to change the lives of patients and their families and bring hope to those who have exhausted their treatment options.

U

Unique

At Syncromune we are doing things that have never been done and developing a disruptive technology that is paving the way for a whole new approach to treating metastatic solid tumor cancers.

R

Relentless

We are focused every day on our pursuit of developing a cure for metastatic solid tumor cancers.  Our team works relentlessly with the goal of helping patients in need. 

E

Ethical

Syncromune is committed to maintaining high standards of personal conduct, practicing honesty in all our professional relationships and endeavors. We believe in being truthful in our actions and words.

Executive Leadership

BIO +

Charles Link, M.D.

Executive Chairman

BIO +

Eamonn Hobbs

President & CEO

BIO +

Gerald Andriole, M.D.

Chief Medical Officer, Urology

BIO +

Kerri-Ann Millar

Chief Financial Officer

BIO +

Zhihong Li, Ph.D.

Chief Regulatory Affairs Officer

BIO +

Agustin Gago

Chief Operating Officer

BIO +

Mario Mautino, Ph.D.

Chief Scientific Officer

Board of Directors

BIO +

Charles Link, M.D.

Executive Chairman

BIO +

Eamonn Hobbs

President & CEO

BIO +

Douglas Watson

Lead Independent Director

BIO +

Jeffrey Cleland, Ph.D.

Director

BIO +

Joseph Maroon, M.D.

Director

BIO +

Norman Schwartz

Director

Scientific Advisory Board

JAMES ARMITAGE, M.D.

  • The Joe Shapiro Professor of Medicine Professor, Division of Oncology & Hematology, UNMC
  • Past President of ASTCT and ASCO

GEORGE C. PRENDERGAST, PH.D.

  • President and CEO of the Lankenau Institute for Medical Research (LIMR)
  • Former Editor-in-Chief of Cancer Research

RICHARD HARRIS, M.D.

  • CEO of UroPartners
  • Past President of Large Urology Group Practice Association (LUGPA) BOD

THOMAS RAFFIN, M.D.

  • Stanford University School of Medicine Colleen and Robert Haas Professor Emeritus of Medicine and Biomedical Ethics
  • Former Chief of Pulmonary and Critical Care Medicine

SUMING WANG, M.D., PH.D.

  • Founded Shanghai Mingda Biotech, an immune therapy company in 2014
  • Former CEO of Shanghai East International Medical Center
  • Vice President of NewLink Genetics from 1999-2008

DAVID VAUGHAN, M.D.

  • Former Chairman of Department of Urology at Florida Hospital & Winter Park Hospital
  • Former Partner of Orlando Urology Associates

Disclaimers: The content on this website is intended for healthcare professionals. The compounds and their uses mentioned on this website are investigational and have not been determined safe and effective by the relevant regulatory authorities, including the US Food and Drug Administration or other applicable agencies in other countries.

Charles Link, M.D.

Executive Chairman
Adjunct Professor, Lankenau Institute for Medical Research

Growing up in southern Ohio in the small town of Bellaire, Dr. Link was appointed to the United States Air Force Academy by Senator John Glenn and majored in chemistry. He completed his medical degree with honors at Stanford University School of Medicine followed by his residency in Internal Medicine at the University of California, San Francisco. He then pursued fellowship training in medical oncology at the National Cancer Institute in Bethesda, Maryland where he joined the US Public Health Service and served as an attending physician in the Ovarian Cancer Section, Medicine Branch, NCI. Dr. Link then served as the Director of the Stoddard Cancer Research Institute and practiced medical oncology for 18 years with Medical Oncology and Hematology Associates of Iowa.

Dr. Link currently serves as an Adjunct Professor at the Lankenau Institute for Medical Research (LIMR) where his work is primarily focused on mechanistic studies and clinical trials to evaluate Syncromune’s SYNC-T Therapy based therapeutic principles.  Dr. Link has conducted research in DNA repair and focused on translational research to develop new cancer treatment approaches. He has designed and conducted clinical studies focused on cancer vaccine technology utilizing the alpha(1,3)galactosyl-epitope to activate the immune response.

Prior to joining Syncromune, Dr. Link was the previous Founder, Chairman and Chief Executive Officer of NewLink Genetics, a clinical-stage company focused on the development of new immuno-oncology treatments. Dr. Link co-founded NewLink Genetics in 1999 with the idea of leveraging the body’s immune system to fight cancer. He also founded BioProtection Systems Corporaton and led the in-licensing of vaccine technologies for life threatening viral infections. 

Dr. Link’s translational research included a long-term collaboration with Dr. David Munn, Medical College of Georgia and Dr. George Prendergast, Lankenau Institute of Medical Research to develop Indolamine 2,3-deoxygenase 1 (IDO1) inhibitors for cancer immunotherapy. This program was partnered with Roche/Genentech in a 1.3-billion-dollar joint venture. In addition, he led the translation program for the first Ebola Vaccine (Ebola Zaire Vaccine) from bench to bedside in collaboration with the Canadian Public Health Service, Walter Reed Army Institute of Research, NIAID, WHO, and Merck, which led to its approval in 2019. He represented the ERVBO program at the WHO series of emergency meetings throughout the Ebola crisis in 2014.

Dr. Link has authored more than 120 scientific articles and has received more than $100 million in funding for his cancer immunotherapy and vaccine development research from organizations including the National Institutes of Health, National Cancer Institute, American Cancer Society, U.S. Army Breast Cancer Program, Susan G. Komen Breast Cancer Foundation, Leukemia and Lymphoma Society, and Department of Defense (US Army and BARDA). He has received recognition throughout his career, including Finalist International Science and Engineering Fair, Research Honors Award from Stanford Medical School, Alpha Omega Alpha Medical Honor Society, NCI EEO Officer’s recognition Award, ASCO Career Development Award, University Fellow Drake University College of Arts and Sciences, Susan G. Komen Foundation Award, Des Moines Business Record Entrepreneur of the Year Award, and Technology Association of Iowa CEO of the Year.

Dr. Link is a highly sought after board member, most recently on the board of NovaScan Corporation in Chicago, QSAM Bioscience (sold to Telix Pharmaceuticals in 2024) and Viewpoint Molecular Targeting, Inc in Iowa (which merged with a NASDAQ company in 2023 to create Perspective Therapeutics). Dr. Link immensely enjoys spending time with his wife, four children and two grandchildren.

Eamonn Hobbs

President & Chief Executive Officer

Mr. Hobbs is an entrepreneurial senior executive with over 35 years of demonstrated success in profitable medical device and combination drug/device product business creation and growth, general management, sales and marketing, and product development. He is a renowned expert in combination drug/device technologies, having developed and commercialized numerous combination products throughout this career.

Previously he was a Visiting Scholar and Entrepreneur in Residence for the Translational Accelerator at Brigham and Women’s Hospital, Harvard Medical School. He has also led several pharmaceutical and biotech companies throughout his career. Formerly he was President and CEO of Antares Pharma, Inc. (NASDAQ: ATRS), a specialty pharmaceutical and drug/device combination company focused on self-injection pharmaceutical products and technologies. Prior to ATRS, he was the President and CEO of Delcath Systems, Inc. (NASDAQ: DCTH), a specialty pharmaceutical and medical device company specializing in a novel drug/device combination cancer therapy.

Prior to Delcath Systems, Inc., Mr. Hobbs served as President and CEO of AngioDynamics, Inc. (NASDAQ: ANGO), a company he co-founded in 1988. He grew the company into a leading medical technology and oncology company which he took public in 2004. ANGO was the best performing medical technology IPO of the class of 2004, also earning the top honors in 2005 and 2006. It was also recognized in Business Week as a “Hot 100 Top Growth Company” for 2005 and 2006 and received a # 11 ranking in Forbes “Best 200 Small Companies” in 2006. Prior to starting AngioDynamics, Mr. Hobbs was Director of Marketing and Product Development at NAMIC; founder, President and CEO of Hobbs Medical, Inc.; and a Product Development Engineer at Cook Incorporated.

He is a highly sought-after board director and has served on numerous public and private company boards throughout his career, including at present 4 other companies in addition to Syncromune. Mr. Hobbs received a B.S. degree in Plastics Engineering with a Biomaterials emphasis at the University of Massachusetts (Lowell).

Gerald Andriole, M.D.

Chief Medical Officer, Urology

Gerald L. Andriole, Jr., M.D. was most recently  Professor and Director of Urology at Johns Hopkins University in the National Capital Region, retiring in June 2023. Previously, he had been the Royce Distinguished Professor and Chief of Urologic Surgery at Washington University in St. Louis for over 20 years.

Dr. Andriole has significant expertise in prostate cancer screening, prevention and treatment. He was continuously funded by NIH from 1993-2021 and has contributed over 450 peer-reviewed publications (H-index of 112).   He chaired the Prostate Committee of NCI’s PLCO Cancer Screening Trial and led the international REDUCE Prostate Cancer Chemoprevention Trial.  He also chaired the Prostate Committee of the Society of Urologic Oncology Clinical Trials Consortium.

Dr. Andriole is an elected member of the American Surgical Association, American Association of Genitourinary Surgeons, and the Clinical Society of Genitourinary Surgeons.  He received the Outstanding Achievement Award from the Urologic Oncology Branch of NCI, the Distinguished Clinician Award from Washington University, the Distinguished Alumni Award from Jefferson Medical College and the Williams Award for Prostate Cancer Research Excellence from the American Urologic Association Urology Care Foundation.

Dr. Andriole participated in the 5-year accelerated medical program at Penn State University and Jefferson Medical College, Philadelphia, PA. He trained in surgery at Strong Memorial Hospital, University of Rochester, NY and completed urology residency at Brigham and Women’s Hospital, Harvard Medical School, Boston, MA. He served a fellowship in Urologic Oncology at the National Cancer Institute of NIH in Bethesda, Maryland prior to joining the faculty at Washington University.

Zhihong Li, Ph.D.

Chief Regulatory Affairs Officer

Dr. Li brings 18 years of regulatory and drug development experience spanning the U.S. FDA, Pfizer, Biocytogen/Eucure and Belief Biomed. He has extensive experience spanning across all phases of drug product life cycle and special expertise regarding clinical development plan, clinical trial design, regulatory strategy to meet US FDA, China NMPA and Australia EC requirements, interpretation and implementation of FDA guidances, ICH guidelines and other regulatory policies. In addition, Dr. Li has working experience in applying FDA expedited programs and special designations such as orphan drug designation.

During his tenure at the FDA’s Center for Drug Evaluation and Research (CDER), Dr. Li conducted regulatory reviews of over 200 INDs, NDAs, and BLAs, providing critical insights into clinical trial design, expedited program applications, and regulatory approvals for oncology and immunotherapy products. In his industry roles, he successfully led multiple IND submissions in the U.S. and China, secured expedited program designations, and guided regulatory pathways for novel biologics, gene therapies, and oncology products. His leadership has helped transition multiple early-stage assets into clinical development and regulatory approval.

As former Chief Regulatory and Strategy Officer at Biocytogen/Eucure, Dr. Li has first-hand experience working with Syncromune’s licensed antibodies (CTLA-4, CD40, and OX40), providing a unique advantage in advancing the company’s immuno-oncology portfolio. Additionally, his fluency in Mandarin and deep understanding of international regulatory environments will strengthen Syncromune’s global partnerships.

Dr. Li completed his Ph.D. at the University of Minnesota Department of Pharmaceutics, and M.S. and B.S. degrees from the Beijing Medical University School of Pharmaceutical Sciences.

Agustin Gago

Chief Operating Officer

Mr. Gago brings to this position over 30 years of experience nurturing, developing and building strong and lasting relationships with the international healthcare community. He has extensive experience on a global basis with industry business partners, ranging from component suppliers to clinical, training and marketing organizations.

Agustin brings a wealth of expertise in the fields of interventional oncology, cancer treatment systems/surgical devices, diagnostic cancer pharmaceuticals as well as cardiology devices and devices for vascular interventions.

Agustin has held several executive-level positions, including: EVP/Chief Commercial Officer at InspireMD, Chief Commercial Officer at Delcath, Vice President of International Oncology Sales at AngioDynamics, and Vice President of International Operations at E-Z-EM Inc.

Over the years Agustin has built direct sales, distributor sales, marketing and distribution organizations, along with technical sales and marketing support units that were focused on the oncology and interventional oncology segments of the marketplace. He holds a B.S. in Business Management from Hofstra University.

Mario Mautino, Ph.D.

Chief Scientific Officer

Dr. Mautino is a senior R&D executive and translational scientist with diverse experience in drug discovery and development, including strategic planning, program management, and intellectual property management. He brings 25+ years of experience in the fields of immuno-oncology, immunology, basic research, medicinal chemistry, bioassays, pharmacology, toxicology, safety pharmacology, clinical pharmacology, IND filings, regulatory guidelines, quality, pharmaceutical development, and drug substance and drug product manufacturing.

He has led multiple research projects related to design of vaccines, and research of combinations of therapeutic modalities in different cancer models including chemotherapy, radiation, vaccination, inhibition of metabolic, and other immune checkpoints.

Douglas Watson

Lead Independent Director

Douglas G. Watson is the founder of Pittencrieff Glen Associates, which was established in June, 1999. Prior to this, he was President and Chief Executive Officer of Novartis Corporation, the US subsidiary of Novartis AG. Mr. Watson’s career spanned 33 years with Geigy/Ciba-Geigy/Novartis, during which time he held a variety of positions in the UK, Switzerland and the US.

From 1986, he was President of Ciba US Pharmaceuticals Division until 1996, when he was appointed President & CEO of Ciba-Geigy Corporation. During this ten year period, Mr. Watson was an active member of the Pharmaceutical Research & Manufacturers Association (PhRMA) board in Washington, DC. In 1997, when Ciba-Geigy & Sandoz merged, Mr. Watson became President & CEO of Novartis Corporation, the US subsidiary of Novartis AG. Mr. Watson elected to take early retirement from Novartis in May, 1999.

Mr. Watson currently serves as a member of the advisory board of Cancer Expert Now Inc. Mr. Watson recently retired as Chairman of the board of OraSure Technologies Inc.

Prior board memberships include Ciba-Geigy Corporation, Novartis Corporation, Engelhard Corporation, Summit Bank Corporation, Wright Medical Group Inc., BioMimetic Therapeutics Inc., BZL Inc., Delcath Systems Inc., Dendreon Corporation, Javelin Pharmaceuticals Inc., Genta Inc., ImmunSYS Inc. and Bionor Immuno AS. He is a former member of the board of the Freedom House Foundation, a non-profit organisation which treats adult men & women recovering from alcohol and drug addiction. He is also a former member of the board of the American Liver Foundation, and a former member of the Advisory Council of the New York Floating Hospital.

Born near Pittencrieff Glen in the city of Dunfermline, Fife, Scotland, Mr. Watson holds an MA degree in pure mathematics from Churchill College, Cambridge University, and is a member of the Chartered Institute of Management Accountants.

Jeffrey Cleland, Ph.D.

Director

Dr. Cleland is currently the Chairman, CEO & President at Ashvattha Therapeutics, Inc. Dr. He has 30 years of industry experience in research and development, including more than a decade at Genentech, Inc. His experience in startups includes major roles in obtaining more than $450 million in capital at stages from Series A through D and exit via IPO including over $300 million in capital raised as CEO. As the founding CEO of Versartis (VSAR), he led one of top biotech IPOs of all time.

After Versartis, he led the Series B financing and clinical translation of novel Johns Hopkins University technology as CEO of Graybug Vision (GRAY). He held executive management positions at BaroFold, Novacea and Targesome, and has managed directly all aspects of drug development and late-stage research.

While at Genentech, Dr. Cleland served in product development and manufacturing roles. He held important leadership roles in the successful approval of two drugs, Herceptin® and Nutropin Depot®, as well as in early work on Lucentis®, Avastin®, and Kadcyla®.

He holds a BS in Chemical Engineering from the University of California, Davis and a PhD in Chemical Engineering from the Massachusetts Institute of Technology. Dr. Cleland has authored more than 100 articles and four books, and holds several issued patents. He serves on the Boards of BIO, Exicure, and Zylem and has advisory roles with small emerging biotechnology companies.

Joseph Maroon, M.D.

Director

Joseph C. Maroon, M.D., Neurosurgeon, Vice Chairman and Professor of the Department of Neurological Surgery at the University of Pittsburgh Medical Center, is regarded as a premiere specialist in the surgical treatment of injuries and diseases of the brain and spine. He is considered an authority in sports medicine and concussion management.

Dr. Maroon is team Neurosurgeon for the Pittsburgh Steelers and Medical Director of World Wrestling Association. He has served on several boards, including Mylan prior to their merger with Upjohn. He has authored over 300 peer-reviewed scientific articles and numerous books. Dr. Maroon’s most recent book is, Square One: A Simple Guide to a Balanced Life. Dr Maroon is a ranked Ironman triathlete and is frequently asked to lecture on wellness, and the benefits of exercise and healthy living.

Norman Schwartz

Director

Mr. Norman D. Schwartz is Chairman of the Board, President, Chief Executive Officer of Bio Rad Laboratories Inc. Mr. Schwartz has been President and Chief Executive Officer since 2003 and Chairman of the Board since 2012. Bio-Rad is a global leader in developing, manufacturing, and marketing a broad range of innovative products for the life science research and clinical diagnostic markets. Bio-Rad is among the top five life science companies in the world, a leading global provider of in-vitro diagnostics supplies and quantification of target DNA or RNA molecules.

Prior to assuming the role of Chief Executive Officer, Mr. Schwartz served as the Vice President, Life Sciences Group, Vice President, Diagnostics Group, President, Nippon Bio-Rad, and Managing Director, Microscience.

Clinical Trials

2919 E. Commercial Blvd.
Fort Lauderdale, FL 33308

info@syncromune.com